(210 days)
The Rubella IgG ELISA test system is an enzyme linked immunosorbent assay (ELISA) intended for the manual or automated (Aptus) qualitative detection of IgG antibodies to Rubella virus in human serum. The test system is intended to be used to evaluate single sera for immune status or paired sera to demonstrate seroconversion, and is for in vitro diagnostic use.
Not Found
The provided text is a 510(k) clearance letter from the FDA for a device named "Aptus (automated) Application for the Rubella IgG ELISA Test System." This document grants market clearance but does not contain the detailed study information, acceptance criteria, or performance data typically found in a clinical study report or a 510(k) summary.
Therefore, I cannot extract the specific information requested in your prompt based on the provided text. The document states that the device is "substantially equivalent" to legally marketed predicate devices, implying that its performance is comparable, but it does not present the detailed results of a study demonstrating this.
To answer your questions, I would need access to the actual 510(k) summary or the underlying study data that was submitted to the FDA for review.
§ 866.3510 Rubella virus serological reagents.
(a)
Identification. Rubella virus serological reagents are devices that consist of antigens and antisera used in serological tests to identify antibodies to rubella virus in serum. The identification aids in the diagnosis of rubella (German measles) or confirmation of a person's immune status from past infections or immunizations and provides epidemiological information on German measles. Newborns infected in the uterus with rubella virus may be born with multiple congenital defects (rubella syndrome).(b)
Classification. Class II. The special controls for this device are:(1) National Committee for Clinical Laboratory Standards':
(i) 1/LA6 “Detection and Quantitation of Rubella IgG Antibody: Evaluation and Performance Criteria for Multiple Component Test Products, Speciment Handling, and Use of the Test Products in the Clinical Laboratory, October 1997,”
(ii) 1/LA18 “Specifications for Immunological Testing for Infectious Diseases, December 1994,”
(iii) D13 “Agglutination Characteristics, Methodology, Limitations, and Clinical Validation, October 1993,”
(iv) EP5 “Evaluation of Precision Performance of Clinical Chemistry Devices, February 1999,” and
(v) EP10 “Preliminary Evaluation of the Linearity of Quantitive Clinical Laboratory Methods, May 1998,”
(2) Centers for Disease Control's:
(i) Low Titer Rubella Standard,
(ii) Reference Panel of Well Characterized Rubella Sera, and
(3) World Health Organization's International Rubella Standard.